

Table SI. Clinicopathological characteristics of all metastatic *KIT/PDGFR*A positive GIST patients (n=119) and their tumors.

Clinicopathological characteristic	n (%)
Sex	
male	60 (50.4)
female	59 (49.6)
Age, years	
median	63.5
range	32-89
≤60	50 (42.0)
>60	69 (68.0)
Imatinib therapy	
yes	116 (97.5)
no	3 (2.5)
Outcome	
alive	48 (40.3)
dead	71 (59.7)
Primary tumor location	
esophagus	5 (4.2)
stomach	44 (37.0)
small intestine	53 (44.5)
rectum	11 (9.2)
other	6 (5.0)
Mitotic rate ^a	
≤5	38 (31.9)
5.1-10	18 (15.1)
>10	68 (57.1)
unknown	1 (0.8)
Risk classification ^b	
High	79 (66.4)
Intermediate	23 (19.3)
Low	13 (10.9)
Very low	1 (0.8)
Unknown	3 (2.5)

GIST, gastrointestinal stromal tumors; ^a, Mitotic rate counted as the number of mitoses per 5 mm²; ^b, Risk group for GIST adapted from Miettinen *et al* (54);